Skip to content

Clinical Study to Compare Visual Performance of Two Trifocal IOLs

Clinical Study to Compare Visual Performance of Two Trifocal IOLs With Different Material (Hydrophobic and Hydrophilic)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03347981
Acronym
PHY1702
Enrollment
53
Registered
2017-11-20
Start date
2017-10-02
Completion date
2019-05-21
Last updated
2021-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Lens Opacities, Presbyopia

Keywords

Intraocular Lens, trifocal, hydrophobic, hydrophilic

Brief summary

Prospective, randomised, controlled, single-surgeon, single-center post-market clinical follow up study to compare the clinical outcomes of two trifocal IOLs with different material

Detailed description

This is a prospective, randomised, controlled, single-surgeon, single-center post-market clinical follow up study whereby patients undergoing routine cataract surgery will have bilateral implantation of trifocal intraocular lenses. The patients will either be implanted with the hydrophobic IOL FineVision POD F GF or the hydrophilic IOL FineVision Pod F. The primary and secondary effectiveness data for visual acuity, contrast sensitivity, halometry, aberrometry, questionnaire outcomes and any adverse events will be collected. Subjects participating in the trial will attend a total of 10 study visits (1 preoperative, 2 operative and 7 postoperative) over a period of 3 months. Subjects would have the option for unscheduled visits if required medically. Primary endpoint data will be collected at the 3 months follow up visit. Data analyses will be done after the last patient finished the final examination to support the study publication plan.

Interventions

Implantation of trifocal IOL POD F GF consisting of hydrophobic material

Implantation of trifocal IOL POD F consisting of hydrophilic material

Sponsors

Beaver-Visitec International, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Cataractous eyes with no comorbidity * Spontaneously emitting the desire for spectacle independence after surgery and with realistic expectation. * Availability, willingness and sufficient cognitive awareness to comply with examination procedures * Signed informed consent

Exclusion criteria

* Irregular astigmatism * Age of patient \< 50 years * Regular corneal astigmatism \>1.00 dioptres by an automatic keratometer or biometer or \>1.25 dioptres if the steep axis of cylinder is between 90° and 120° in one or both eyes * Difficulty for cooperation (distance from their home, general health condition) * Acute or chronic disease or illness that would increase risk or confound study results (e.g. diabetes mellitus (with retinopathy), immunocompromised, glaucoma etc…) * Any ocular comorbidity * History of ocular trauma or prior ocular surgery including refractive procedures * Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome) * Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions) * AMD suspicious eyes (determined by OCT) * Complicated surgery

Design outcomes

Primary

MeasureTime frameDescription
monocular Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions.3 months postoperativeThe primary study end point is to show statistically equal visual acuity outcomes between both study groups. The primary study endpoint parameter is monocular Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions. UDVA is measured with ETDRS charts placed in 4m distance according to ISO 11979-7:2014

Secondary

MeasureTime frameDescription
Manifested refraction - Sphere3 months postoperativeThe spherical part of the manifested refraction is measured by means of a phoropter. The examination is done according to ISO 11979-7:2014.
Manifested refraction - Cylinder3 months postoperativeThe cylindrical part of the manifested refraction is measured by means of a phoropter. Amount of cylinder and cylinder axis will be noted. The examination is done according to ISO 11979-7:2014. This data will also be used to calculate the manifested refractive spherical equivalent (MRSE)
Uncorrected Distance Visual Acuity (UDVA)3 months postoperativeUDVA is measured with ETDRS charts placed in 4m distance according to ISO 11979-7:2014. This assessment is done binocularly.
Distance Corrected Intermediate Visual Acuity at 80cm (DCIVA)3 months postoperativeDCIVA is measured with Radner reading charts placed in 80cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
Distance Corrected Intermediate Visual Acuity at 63cm (DCIVA)3 months postoperativeDCIVA is measured with ETDRS charts placed in 63cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
Distance Corrected Near Visual Acuity at 40cm (DCNVA)3 months postoperativeDCNVA is measured with Radner reading charts placed in 40cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
Distance Corrected Near Visual Acuity at 25cm (DCNVA)3 months postoperativeDCNVA is measured with Radner reading charts placed in 25cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
Halometry3 months postoperativeHalometry outcomes, measurement by halos software v1.0
Corrected Distance Visual Acuity (CDVA)3 months postoperativeCDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
Aberrometry - SA3 months postoperativeAberrometry outcomes are measured with a standard aberrometer. In this examination, the following values will be evaluated: Spherical aberration
Aberrometry - HOA3 months postoperativeAberrometry outcomes are measured with a standard aberrometer. In this examination, the following values will be evaluated: High Order Aberrations
Aberrometry - Tilt3 months postoperativeAberrometry outcomes are measured with a standard aberrometer. In this examination, the following values will be evaluated: lens tilt
OQAS II - OSI3 months postoperativeOutcomes of OQAS II diagnostic device (Ocular Scatter Index)
OQAS II - MTF3 months postoperativeOutcomes of OQAS II diagnostic device (Modular Transfer Function)
OQAS II - Strehl Ratio3 months postoperativeOutcomes of OQAS II diagnostic device (Strehl Ratio)
questionnaire3 months postoperativeOutcomes measures of a questionnaire to address the general patient satisfaction and possible side effects of the treatment. For this study, the validated and verified questionnaire VFQ-25 (National Eye Institute) will be used. The maximum score for each question is 100. The scoring and evaluation of the questionnaire will be done according to the official guidelines and manual provided by National Eye Institute
Contrast Sensitivity3 months postoperativeContrast Sensitivity under photopic and mesopic light conditions using the standardized contrast sensitivity device CSV-1000 (VectorVision)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026